
News|Articles|December 1, 2001
Bioterror response to alter pharmaceutical development and marketing
Uncle Sam is poised to authorize more than $1 billion to buy medicines and vaccines for the national pharmaceutical stockpile, and federal agencies are gearing up to spend millions more on research related to infectious disease. In response, the pharmaceutical industry is assessing how these developments may alter the way it does business.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Who will pay for Trump program to have Medicare cover GLP-1s for obesity?
2
Parsing the sizable life expectancy gap for people with schizophrenia
3
Relmada Therapeutics appoints Max Kates to clinical advisory board to support NDV-01 phase 3 program for bladder cancer
4
Wearable patch could flag melanoma risk earlier than visual inspection
5




















































